In this study, genetic analysis was performed on Plasmodium vivax and Plasmodium falciparum parasites isolated from peripheral and placental blood in pregnant women living in north-west Colombia, and compared with parasites causing acute malaria in non-pregnant populations.
Here we tested the ability of DBL4ɛ-ID4 to induce binding-inhibitory antibodies when formulated with adjuvants approved for human use.
Placental malaria is a significant cause of all malaria-related deaths globally for which no drugs have been developed to specifically disrupt its pathogenesis.
We addressed whether Plasmodium falciparum placental infection could additionally be associated with the risk of nonmalaria fevers in infants.
We have evaluated the agreement (kappa coefficient) between microscopy and a Plasmodium falciparum histidine-rich protein 2 (HRP2)-based immuno-chromatographic test (ICT) on placental blood from 1151 women at delivery.
This study was conducted at the Gushegu District Hospital in Ghana from June to August 2010. Sulfadoxine-pyrimethamine (SP) was used as intermittent preventative treatment (IPT) during pregnancy.
As malaria has powerful immunomodulatory effects, we tested the hypothesis that PM predicts reduced T-cell responses to vaccine challenge.
One hundred and seven placentae were investigated for malaria infection using polymerase chain reaction (PCR) and histology.
These results demonstrate that the DBL4ɛ-ID4 antigen is highly immunogenic and that binding inhibitory antibodies are induced when formulated with any of the tested adjuvants.
The concept of developmental origins of health and disease and the epidemic of noncommunicable diseases in low- and middle-income countries has increased the focus on low birth weight (LBW).